GSK and Alector terminated a Phase 2 Alzheimer’s trial after an interim analysis indicated the study was unlikely to meet its primary endpoint. The stop reflects continued difficulty translating late-stage Alzheimer’s strategies into clinically meaningful outcomes. The decision triggers additional program reprioritization across GSK’s neurology pipeline and leaves Alector with a reallocation of capital and development focus. While details of the endpoint and biomarker trends were not included in the report, the interim futility finding was decisive. For biotech investors and operators, the read-through is on trial gating: interim analyses continue to shorten timelines and increase the value of early evidence generation for cognitive and disease progression outcomes. The development also highlights how long-duration CNS programs are increasingly managed like asset portfolios, with rapid exits when primary objectives look out of reach.